BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35512522)

  • 1. YTHDF2 is a novel diagnostic marker of endometrial adenocarcinoma and endometrial atypical hyperplasia/ intraepithelial neoplasia.
    Bian PP; Liu SY; Luo QP; Xiong ZT
    Pathol Res Pract; 2022 Jun; 234():153919. PubMed ID: 35512522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
    Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
    Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
    Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
    Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
    Xiong Y; Xiong YY; Zhou YF
    Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma.
    Xiong Y; Xiong YY; Zhou YF
    Eur J Gynaecol Oncol; 2010; 31(2):160-4. PubMed ID: 20527231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL-2 and PAX2 Expressions in EIN which Had Been Previously Diagnosed as Non-Atypical Hyperplasia.
    Trabzonlu L; Muezzinoglu B; Corakci A
    Pathol Oncol Res; 2019 Apr; 25(2):471-476. PubMed ID: 29270778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of a PAX2, PTEN, and β-catenin Panel in the Diagnosis of Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia in Endometrial Polyps.
    Lucas E; Niu S; Aguilar M; Molberg K; Carrick K; Rivera-Colon G; Gwin K; Wang Y; Zheng W; Castrillon DH; Chen H
    Am J Surg Pathol; 2023 Sep; 47(9):1019-1026. PubMed ID: 37314146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear expression of β-catenin in endometrial hyperplasia as marker of premalignancy.
    Travaglino A; Raffone A; Saccone G; Mascolo M; D'Alessandro P; Arduino B; Mollo A; Insabato L; Zullo F
    APMIS; 2019 Nov; 127(11):699-709. PubMed ID: 31403731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal p16 expression is significantly increased in endometrial carcinoma.
    Yoon G; Koh CW; Yoon N; Kim JY; Kim HS
    Oncotarget; 2017 Jan; 8(3):4826-4836. PubMed ID: 27902476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology].
    Lax S
    Pathologe; 2011 Nov; 32 Suppl 2():255-64. PubMed ID: 22033684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Morphological diagnosis of endometrial intraepithelial neoplasia and expression of PTEN].
    Zhou WX; Liang ZY; Gao J; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2009 Jun; 38(6):393-6. PubMed ID: 19781346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endometrial Intraepithelial Neoplasia (EIN) in endometrial biopsy specimens categorized by the 1994 World Health Organization classification for endometrial hyperplasia.
    Li XC; Song WJ
    Asian Pac J Cancer Prev; 2013; 14(10):5935-9. PubMed ID: 24289604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Campanino MR; Mollo A; De Placido G; Insabato L; Zullo F
    Acta Obstet Gynecol Scand; 2019 Mar; 98(3):275-286. PubMed ID: 30511743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?
    Lucas E; Chen H; Molberg K; Castrillon DH; Rivera Colon G; Li L; Hinson S; Thibodeaux J; Lea J; Miller DS; Zheng W
    Int J Gynecol Pathol; 2019 Nov; 38(6):533-542. PubMed ID: 30383610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pax2 expression in simultaneously diagnosed WHO and EIN classification systems.
    Joiner AK; Quick CM; Jeffus SK
    Int J Gynecol Pathol; 2015 Jan; 34(1):40-6. PubMed ID: 25473752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma.
    Canpolat T; Ersöz C; Uğuz A; Vardar MA; Altintaş A
    Turk Patoloji Derg; 2016; 32(3):141-7. PubMed ID: 27562387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma.
    Chapel DB; Patil SA; Plagov A; Puranik R; Mendybaeva A; Steinhardt G; Wanjari P; Lastra RR; Kadri S; Segal JP; Ritterhouse LL
    Mod Pathol; 2019 Oct; 32(10):1508-1520. PubMed ID: 31186530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases.
    Němejcová K; Rosmusová J; Bártů M; Důra M; Tichá I; Dundr P
    Int J Surg Pathol; 2017 Aug; 25(5):389-396. PubMed ID: 28381136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.
    Allison KH; Upson K; Reed SD; Jordan CD; Newton KM; Doherty J; Swisher EM; Garcia RL
    Int J Gynecol Pathol; 2012 Mar; 31(2):151-159. PubMed ID: 22317873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium.
    Cirpan T; Terek MC; Mgoyi L; Zekioglu O; Iscan O; Ozsaran A
    Eur J Gynaecol Oncol; 2006; 27(4):389-92. PubMed ID: 17009632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.